Search clinical trials for: AS902330

Total 4 results

Merck KGaA, Darmstadt, Germany

Terminated

Sprifermin (AS902330) in Cartilage Injury Repair (CIR)

Isolated Cartilage Injury of the Knee

Germany
Merck KGaA, Darmstadt, Germany
Merck Serono S.A., Geneva

Completed

Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement

Knee Osteoarthritis

Denmark, Finland, Sweden, United Kingdom, Bulgaria, South Africa
EMD Serono

Terminated

A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee

Cartilage Injury of Knee
Merck KGaA, Darmstadt, Germany

Completed

A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery

Knee Osteoarthritis

Germany, Croatia, Bulgaria, Canada, Finland, Poland, Serbia, South Africa, Sweden

3

Subscribe